title: Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin.
abstract: The primary aim of this study was to evaluate the effect of pioglitazone on endothelial function, as assessed by flow-mediated dilatation (FMD) nitroglycerine-induced dilatation (NID) in patients with type 2 diabetes mellitus treated with insulin. A randomized double-blind placebo-controlled trial involved 20 patients with insulin-treated type 2 diabetes. Patients received either pioglitazone 30 mg or placebo for 4 months. FMD, NID, and HbA1c were measured before and after 4 months of treatment. HbA1c decreased from 10.0 (+/- 2.3) to 8.4 (+/- 2.0) in the pioglitazone group, a statistically significant improvement in glycemic control (p = 0.018). HbA1c was unchanged in the placebo group (p = 0.477). Endothelial function as assessed by FMD significantly improved from 10.1 (+/- 4.0)% to 14.6 (+/- 6.2)% in the pioglitazone group (p = 0.036) as compared to the placebo group (p = 0.705). There was a trend towards improvement in the NID in the pioglitazone group (from 13.3 +/- 8.0% to 18.9 +/- 5.4%; p = 0.056). In insulin-treated patients with type 2 diabetes, the addition of pioglitazone improves endothelial function, as measured by FMD. Addition of pioglitazone to insulin in type 2 diabetes patients may favorably impact vascular function in diabetes, even after many years of insulin resistance and hyperglycemia.
authors: Department of Medicine/Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana., Department of Medicine, Veterans Affairs Medical Center, New Orleans, Louisiana.
authors: Sunil
authors: S
authors: Asnani
authors: Biju
authors: B
authors: Kunhiraman
authors: Ali
authors: A
authors: Jawa
authors: Donald
authors: D
authors: Akers
authors: David
authors: D
authors: Lumpkin
authors: Vivian
authors: V
authors: Fonseca